Corcept Therapeutics. has been granted a patent for a class of pyrimidinedione cyclohexenyl compounds, which are identified as glucocorticoid receptor modulators. The patent includes specific claims regarding the chemical structure of these compounds. GlobalData’s report on Corcept Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Corcept Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Corcept Therapeutics's grant share as of June 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Pyrimidinedione compounds as glucocorticoid receptor modulators
The granted patent US12018001B2 outlines a novel compound characterized by a specific chemical formula, referred to as formula Ic-1. The claims detail various structural components of the compound, particularly focusing on the substituents represented as Rb, which can independently be a range of groups including hydrogen, halogens, cyano groups, and various alkyl and alkoxy chains. The claims further elaborate on the diversity of Rb substituents, allowing for a wide array of chemical variations, including specific functional groups such as amines, sulfonyl groups, and cyclic structures. This flexibility in substituent choice suggests potential for tailoring the compound's properties for specific applications.
Additionally, the patent claims include provisions for the compound's use in pharmaceutical compositions, indicating that it may be combined with one or more pharmaceutically acceptable excipients. This suggests a potential therapeutic application, although the specific uses or indications are not detailed in the claims. The patent also lists several specific compounds derived from the general formula, indicating a focus on particular derivatives that may exhibit desirable biological or chemical properties. Overall, the claims present a comprehensive framework for a compound with significant structural variability, which may be leveraged for various pharmaceutical applications.
To know more about GlobalData’s detailed insights on Corcept Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
